Literature DB >> 21185919

Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor.

Fanghua Qi1, Anyuan Li, Yoshinori Inagaki, Norihiro Kokudo, Sumihito Tamura, Munehiro Nakata, Wei Tang.   

Abstract

The skin of the toad Bufo bufo gargarizans Cantor is known to be rich in bufadienolides, peptides and alkaloids. It has been found to be a source of some extracts and biologically active compounds with antitumor activity. Cinobufacini (Huachansu), a Chinese medicine prepared from the dried toad skin, has been widely used in clinical therapy for various cancers in China. Bufadienolides, such as bufalin, cinobufagin, resibufogenin, and telocinobufagin, are the major active compounds derived from the toad skin. They are the maker biologically active compounds of cinobufagin while the antitumor activity of cinobufagin may be due to this kind of components. Experimental research has suggested that cinobufacini and its active compounds (e.g. bufalin and cinobufagin) exhibit significant antitumor activity, including inhibition of cell proliferation, induction of cell differentiation, induction of apoptosis, disruption of the cell cycle, inhibition of cancer angiogenesis, reversal of multi-drug resistance, and regulation of the immune response. Clinical data have indicated that cinobufacini may have effective anticancer activity with low toxicity and few side effects. Data to date suggest it may also enhance quality of life for patients with cancer. Thus, this review briefly summarizes recent studies on the anticancer activity of cinobufacini and some of its active compounds from the skin of the toad Bufo bufo gargarizans Cantor. This might provide additional evidence for further study of the extracts and active compounds from the toad skin in cancer treatment.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21185919     DOI: 10.1016/j.intimp.2010.12.007

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  75 in total

1.  Anticancer effects of 5-fluorouracil combined with warming and relieving cold phlegm formula on human breast cancer.

Authors:  Xue-Lin Wang; Feng Ma; Xiong-Zhi Wu
Journal:  Chin J Integr Med       Date:  2011-12-08       Impact factor: 1.978

Review 2.  Angel of human health: current research updates in toad medicine.

Authors:  Qian Yang; Xuanxuan Zhou; Meng Zhang; Linlin Bi; Shan Miao; Wei Cao; Yanhua Xie; Jiyuan Sun; Haifeng Tang; Ying Li; Qing Miao; Siwang Wang
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

3.  Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.

Authors:  Xiao-Yu Dai; Bao-Feng Zhou; Yang-Yang Xie; Jie Lou; Ke-Qiang Li
Journal:  Oncol Lett       Date:  2018-03-23       Impact factor: 2.967

4.  Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.

Authors:  Shunchao Yan; Xiujuan Qu; Chong'an Xu; Zhitu Zhu; Lingyun Zhang; Ling Xu; Na Song; Yuee Teng; Yunpeng Liu
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-24       Impact factor: 4.553

5.  Resibufogenin suppresses tumor growth and inhibits glycolysis in ovarian cancer by modulating PIM1.

Authors:  Qian Li; Chuanwu Jiang; Yan Wang; Minghua Wei; Huijin Zheng; Yanqi Xu; Xuegang Xu; Fengyu Jia; Kai Liu; Gang Sun; Jianhua Zang; Ping Mo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-10       Impact factor: 3.000

6.  Bufalin derivative BF211 inhibits proteasome activity in human lung cancer cells in vitro by inhibiting β1 subunit expression and disrupting proteasome assembly.

Authors:  Peng Sun; Li-Xing Feng; Dong-Mei Zhang; Miao Liu; Wang Liu; Tian Mi; Wan-Ying Wu; Bao-Hong Jiang; Min Yang; Li-Hong Hu; De-An Guo; Xuan Liu
Journal:  Acta Pharmacol Sin       Date:  2016-05-30       Impact factor: 6.150

7.  Safety reassessment of cinobufotalin injection: new findings into cardiotoxicity.

Authors:  Min Li; Xijie Wang; Yunliang Qiu; Yizhe Zhang; Xueying Pan; Naping Tang; Tao Chen; Bing Ruan; Shuming Shao; Liang He; Hua Li; Jing Ma
Journal:  Toxicol Res (Camb)       Date:  2020-06-12       Impact factor: 3.524

8.  Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation.

Authors:  Zhuo Yu; Hai Feng; Yunhui Zhuo; Man Li; Xiaojun Zhu; Lingying Huang; Xin Zhang; Zhenhua Zhou; Chao Zheng; Yun Jiang; Fan Le; Dae-Yeul Yu; Alfred Szelok Cheng; Xuehua Sun; Yueqiu Gao
Journal:  Cell Oncol (Dordr)       Date:  2020-07-04       Impact factor: 6.730

9.  Bufalin inhibited the growth of human osteosarcoma MG-63 cells via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway.

Authors:  Dewei Wang; Zhenggang Bi
Journal:  Tumour Biol       Date:  2014-02-26

10.  Tumor-targeting efficacy of a BF211 prodrug through hydrolysis by fibroblast activation protein-α.

Authors:  Xiao-Ping Chai; Guang-Long Sun; Yan-Fen Fang; Li-Hong Hu; Xuan Liu; Xiong-Wen Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-11-09       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.